Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Onpattro
Pharma
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
At the ESC conference, Alnylam presented data from a key trial which assessed Amvuttra as a treatment for transthyretin amyloid cardiomyopathy.
Kevin Dunleavy
Aug 30, 2024 10:06am
FDA spurns Alnylam's Onpattro in ATTR-CM despite adcomm backing
Oct 9, 2023 9:54am
Pfizer's tafamidis will hold its own against new meds: analysts
Sep 18, 2023 3:05pm
Alnylam wins expert backing for Onpattro in rare heart disease
Sep 13, 2023 5:30pm
FDA casts doubt on Alnylam's Onpattro in ATTR-CM
Sep 11, 2023 11:15am
Alnylam to face FDA AdComm for Onpattro's ATTR-CM bid
Feb 21, 2023 10:53am
